UC respects today’s ‘no-interference-in-fact’ decision by the PTAB and is pleased that its patent application covering the use of CRISPR-Cas9 gene editing technology for all cell types can now move closer to issuance,” said Paul Alivisatos, UC Berkeley vice chancellor for research and professor of chemistry.